South Africa Central Nervous System Therapeutic Market to 2027 - Regional Analysis and Forecasts by Disease Type; Drug Type; Distribution Channel and Geography

The South Africa Central Nervous System (CNS) Therapeutic market is expected to reach US$ 3,686.91 Mn in 2027 from US$ 2,267.59 Mn in 2018. The market is estimated to grow with a CAGR of 5.6% from 2019-2027.

Rising prevalence of CNS diseases such as malnutrition, malaria, the human immunodeficiency virus & the acquired immune deficiency syndrome (HIV/AIDS), and demographic transitions are expected to surge the market growth. However, high cost of treatment is likely to have a negative impact on the growth of the market in the coming years.

According to a data of NCBI in 2014, approximately one in three South Africans will undergo a mental disorder in a lifetime, and the prevalence is higher than various low- and middle-income countries. Moreover, as per the data of South African Journal of Psychiatry, published in 2017, in a South African population-based national study, states that the prevalence of drug use was 3.7%. The highest prevalence was for cannabis, which was 3.3%, followed by sedatives or sleeping pills to be 0.8%, amphetamine-type stimulants around 0.7% and hallucinogens, to be 0.5%. Furthermore, HIV-associated dementia (HAD) is dominant in 15-30% of untreated adults with late-stage disease. The elderly patients, who previously have an increased risk of non-AIDS related dementias, are more prone to untreated HIV. Such a rising prevalence of CNS disorders is expected to create a demand for the central nervous system (CNS) therapeutic across the world.

South Africa Central Nervous System (CNS) Therapeutic market, based on Disease Type was segmented into Neurovascular Diseases, Degenerative Disorders, Mental Health, Trauma, Others). Moreover, the Degenerative Disorders segment held largest market share owing to increasing cases of diseases. . In 2016, according to World Health Organization (WHO), it was estimated that 6.1 million individuals worldwide had Parkinson's disease, and in South Africa, around three percent of the population (50 million) suffers from the disease.

South Africa central nervous system (CNS) therapeutic market, based on drug type was segmented into analgesics, nervous system drugs, anesthetics, anti-parkinson drugs, anti-epileptics, others. Moreover, analgesics segment is expected to grow at the fastest rate during the coming years because they are used to relive pain which provides relief to patients without being consciousness.

South Africa Central Nervous System (CNS) Therapeutic market, based on Distribution Channel was segmented into Hospital Pharmacies, Retail Pharmacies. In 2018, the hospitals segment held the largest share of the market, by Distribution Channel. Moreover, same segment is expected to grow at the fastest rate during the coming years because In hospitals, therapy and treatments of patients can be performed under one roof, which minimizes the need to visit pharmacies and thereby increasing the utilization of hospital settings.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the central nervous system therapeutics market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the central nervous system therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.